Let’s rewind to Year 10 biology- you know that mitochondria is the powerhouse of the cell, chances are you vaguely remember the golgi apparatus but do you remember what an exosome is? Exosomes, or extracellular vesicles are little packages delivering molecules and enhancing cell-to-cell communication. Clinical- stage biopharmaceutical company Exopharm (ASX: EX1) is utilising exosomes
Read More
When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world. By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on
Read More
Once upon a time, stress ensured our survival. When faced with a dangerous situation our body responds instantly- heart rate increases, blood pressure climbs and muscles tighten as the body prepares to deal with the bear/ exam you’ve been presented with. In the modern world we are faced with a disproportionately higher amount of exams
Read More
Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights
Read More
Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression. 3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment
Read More
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read More